Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-264 in Type 1 Diabetes Mellitus
NCT05791201Phase 2Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- May 2023
- Primary completion
- Mar 2027
- Modality
- Cell Therapies, Device-based Delivery
- Countries
- 7
01
Overview
A Phase 2 trial of VX-264 in type 1 diabetes mellitus (T1D), sponsored by Vertex Pharmaceuticals. Started May 2023; status: active, not recruiting.
02
Drugs
VX-264
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05791201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05791201.